Welcome to our 2024 Annual Review

Chairman’s message

Future digital solutions and clinical expertise in our specialized areas will bring us closer than ever to medical professionals, allowing us to improve patient care. Marc Rubiralta Chairman

CEO interview

We exceeded our sales budget across all geographies, regions, and most of our business units. Diagnostics sales grew by 6% at constant exchange rate and constant perimeter compared to 2023. And we also increased our operating income. Carlos Pascual CEO

Werfen in brief

We recorded a +6% increase in revenues, and improved operating income for 2024. With strong performances across all of our geographies and most of our business units, including Hemostasis and Acute Care, we launched groundbreaking new products, invested in our technology centers and continued to invest heavily in R&D.

Launch of revolutionary GEM® Premier™ 7000

The first-ever rapid point of care blood gas testing system with integrated hemolysis detection.

Learn more
Image of five compact medical analyzers with sleek black tops and gray bottoms. Below them, a monitor displays a software interface with colorful icons and options. The setup suggests a laboratory or medical environment, perfect for the Annual Review of advancements in medical technology.

Launch of ACL TOP® Family 70

ACL TOP® Family 70 Series Hemostasis Testing Systems, now with automated performance verification tools, for unmatched operational efficiency.

Learn more
Aerial view of a large industrial facility surrounded by greenery, currently preparing for its Annual Review. The building has a flat roof with several sections and a parking lot filled with cars. In the background, open fields and what appears to be a runway stretch into the horizon.

Opening of a new building

At Hemostasis and Acute Care Diagnostics Technology Center in Bedford, MA, USA, expanding our capabilities for innovation in Specialized Diagnostics.

Learn more

Acquisition of Transplant Technology Center building

In Waukesha, Wisconsin, solidifying our commitment to this growing business unit.

Business highlights in 2024

Sales of € 2.2 bln in 2024, +6% YOY

Net debt & leverage ratio fell from 3.5x to 3.0x

Retained our market-leading positions worldwide and reported growth across all of our regions and territories.

Divestment of our Medical Device distribution business, furthering our focus on specialized diagnostics.

Acquisition of Omixon brings comprehensive Next Generation Sequencing (NGS) portfolio, robust bioinformatics capabilities, and innovative pipeline of solutions to our Transplant business unit.

Market position worldwide

Our leading positions are backed by the quality of our solutions, our innovation capabilities and heavy investment in R&D.

Note: All sales growth numbers are at Constant Exchange Rate and Constant Perimeter.